Page 1

Logo NEWS RELEASE SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update 8/12/2021 Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut - S ( GPS ) in Combination with PD - 1 Inhibitors for Malignant Pleural Mesothelioma ( MPM ) and WT1 + Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia ( AML ) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $ 29.9 million as of June 30 , 2021 To Host Virtual Investor Symposium on GPS on August 17 , 2021 NEW YORK , Aug. 12 , 2021 ( GLOBE NEWSWIRE ) -- SELLAS Life Sciences Group , Inc. ( NASDAQ : SLS ) ( " SELLAS " or the " Company " ) , a late - stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications , today reported its financial results for the quarter ended June 30 , 2021 and provided a business update . " We were pleased to report in June updated clinical data for our two earlier stage studies of GPS in combination with PD - 1 inhibitors - the combination of GPS with nivolumab ( OpdivoⓇ ) in MPM patients and GPS with pembrolizumab ( Keytruda® ) in advanced ovarian cancer patients . We will continue our analyses as we collect more data over the remainder of the year , " said Angelos Stergiou , MD , ScD . h.c. , President and Chief Executive Officer of SELLAS . " We also activated additional clinical sites and continued to enroll patients in the United States and Europe for our Phase 3 REGAL study of GPS in AML patients , and expect to activate additional sites in the European Union ( EU ) as well as other countries outside of the EU throughout the remainder of 2021. " " Also , we note recently published data in the journal Bone Marrow Transplantation regarding the outcomes of AML patients , including those who undergo transplant , which clearly shows that there continues to be a large unmet 1